



Saffron – *Crocus sativus*

Common Indications:

- Major Depressive Disorder (MDD)
- Cognitive Support and Alzheimer's Dementia
- Premenstrual Syndrome (PMS)
- SSRI-induced Sexual Dysfunction
- Age Related Macular Degeneration (ARMD)
- Immunomodulation

General Comments:

Saffron is a classic staple of traditional Persian, Greco-Arabic, and Ayurvedic medicine. Derived from the carefully hand-harvested stigmas of *Crocus sativus*, it represents the world's most costly botanical. Saffron exerts broad-spectrum therapeutic influence across the central nervous, ophthalmic, reproductive, and immune systems as a potent anti-inflammatory, neuroprotective, and mood-regulating agent.

Benefits & Mechanism of Action:

Neuroprotection & Mood Support (MDD)

The bioactive elements of saffron (specifically crocin and safranal) exert powerful antidepressant effects through dual neural pathways: (1) Monoamine Reuptake Inhibition: In vivo research confirms that safranal and crocin inhibit the synaptic reuptake of serotonin, dopamine, and noradrenaline. (2) Neurotrophic Upregulation: Saffron significantly increases expression of CREB (cAMP response element-binding protein), BDNF (brain-derived neurotrophic factor), and VGF neuropeptides in the hippocampus. Double-blind RCTs demonstrate that 30 mg/day achieves therapeutic outcome equal to standard synthetic antidepressants (Fluoxetine 20–40 mg/day; Imipramine 100 mg/day) with significantly fewer anticholinergic and sedative side effects.

Cognitive Health & Dementia (Alzheimer's)

Saffron exhibits moderate acetylcholinesterase (AChE) inhibition. Active constituents crocetin and dimethylcrocetin bind simultaneously to both the catalytic and peripheral anionic sites of the AChE enzyme. Furthermore, crocin inhibits neuronal apoptosis by modulating Bcl-2 family proteins, suppressing cytochrome c release and oxidative damage. Studies show in mild-to-moderate AD patients, 30 mg/day produced cognitive gains equivalent to Donepezil (10 mg/day) with superior gastrointestinal tolerability (significantly less vomiting).

Ophthalmic Protection (ARMD)

High concentrations of antioxidant carotenoids (crocin and crocetin) protect retinal photoreceptors against oxidative stress and ischemia. Clinical trials in patients with early ARMD demonstrate that oral saffron at 20 mg/day significantly increases central retinal flicker sensitivity within 3 months, with visual benefits sustained over 14 months of extended therapy.

Endocrine, Reproductive & Immune Modulation

Saffron significantly reverses fluoxetine-induced sexual dysfunction in women over 4 weeks (improving total FSFI scores for arousal, lubrication, and pain reduction). In women with PMS, 30 mg/day significantly reduces premenstrual distress and HAM-D depression scores over 2 cycles. At 100 mg/day, saffron transiently elevates IgG antibody levels while balancing monocyte/basophil ratios.

DOSE:

- Major Depressive Disorder (MDD): 30 mg/day (15 mg twice daily) of standardized stigma or petal extract.
- Alzheimer's Dementia (AD): 30 mg/day (15 mg twice daily).
- Premenstrual Syndrome (PMS): 30 mg/day (15 mg twice daily) over at least 2 menstrual cycles.
- SSRI-Induced Sexual Dysfunction: 30 mg/day for 4 weeks.
- Age-Related Macular Degeneration (ARMD): 20 mg/day daily long-term.
- Immunomodulation: 100 mg/day short-term (3 weeks).

STANDARDIZATION:

Saffron extract preparations should be standardized to contain key bioactive constituents: water-soluble carotenoids (crocin ~10%), monoterpene aldehydes (safranal for aroma), and bitter glycosides (picrocrocin).

CAUTIONS & SIDE EFFECTS:

- Pregnancy Contraindication: High therapeutic doses of saffron must be avoided during pregnancy. Preclinical animal studies show high doses of crocin and safranal cause fetal growth retardation, reduced length/weight, and skeletal malformations. Standard culinary amounts are likely safe.
- Concomitant Antidepressant Use: Due to saffron's potent monoaminergic activity, concurrent use with prescription antidepressants requires close medical supervision.

Pharmaceutical antidepressant requirements may decrease when taken alongside therapeutic doses

- Exceptional Safety Window: Saffron possesses an extremely high toxicity threshold (LD = 20 g/kg). Clinical 50 doses (15–30 mg/day) are exceptionally well tolerated with adverse event rates comparable to placebo.

References:

Major Depressive Disorder (MDD)

1. Akhondzadeh S, et al. (2005). *Crocus sativus* L. in the treatment of mild to moderate depression: a double-blind, randomized and placebo-controlled trial. *Phytotherapy Research*, 19(2), 148–151.
2. Akhondzadeh S, et al. (2004). Comparison of *Crocus sativus* L. and imipramine in the treatment of mild to moderate depression: a pilot double-blind randomized trial. *BMC Complementary and Alternative Medicine*, 4, 12.
3. Hausenblas HA, et al. (2013). Saffron (*Crocus sativus* L.) and major depressive disorder: a meta-analysis of randomized clinical trials. *Journal of Integrative Medicine*, 11(6), 377–383.
4. Moshiri E, et al. (2006). *Crocus sativus* L. (petal) in the treatment of mild-to-moderate depression: a double-blind, randomized and placebo-controlled trial. *Phytomedicine*, 13(9–10), 607–611.
5. Noorbala AA, et al. (2005). Hydro-alcoholic extract of *Crocus sativus* L. versus fluoxetine in the treatment of mild to moderate depression: a randomized, double-blind, unit-randomized clinical trial. *Journal of Ethnopharmacology*, 97(2), 281–284.
6. Shahmansouri N, et al. (2014). A randomized, double-blind clinical trial comparing the efficacy and safety of *Crocus sativus* L. with fluoxetine for improving mild to moderate depression in post-PCI patients. *Journal of Affective Disorders*, 155, 216–222.
7. Valadi H, et al. (2010). Antidepressant-like effect of crocin and its efficacy on transcript level of CREB, BDNF and VGF in rat hippocampus. *Daru*, 18(4), 281–285.

Alzheimer's Dementia & Cognition

8. Akhondzadeh S, et al. (2010a). Saffron in the treatment of patients with mild to moderate Alzheimer's disease: a 16-week, randomized and placebo-controlled trial. *Journal of Clinical Pharmacy and Therapeutics*, 35(5), 581–588.
9. Akhondzadeh S, et al. (2010b). A 22-week, multicenter, randomized, double-blind controlled trial of *Crocus sativus* in the treatment of mild-to-moderate Alzheimer's disease. *Psychopharmacology (Berl)*, 207(4), 637–643.
10. Geromichalos GD, et al. (2012). Saffron as a source of novel acetylcholinesterase inhibitors: molecular docking and *in vitro* enzyme kinetics studies. *Journal of Agricultural and Food Chemistry*, 60(24), 6131–6138.
11. Pitsikas N, et al. (2007). Effects of the active constituents of *Crocus sativus* L., crocins, on recognition and spatial rats' memory. *Behavioural Brain Research*, 183(2), 141–146.

12. Soeda S, et al. (2001). Crocin suppresses tumor necrosis factor-alpha-induced cell death in neuronally differentiated PC-12 cells. *Life Sciences*, 69(17), 1967–1977.

Sexual Dysfunction & Premenstrual Syndrome (PMS)

13. Agha-Hosseini M, et al. (2008). *Crocus sativus* L. (saffron) in the treatment of premenstrual syndrome: a double-blind, randomised and placebo-controlled trial. *BJOG: An International Journal of Obstetrics & Gynaecology*, 115(4), 515–519.
14. Hosseinzadeh H, et al. (2008). Evaluation of the aphrodisiac activity of *Crocus sativus* L. stigma extract and its constituents, crocin and safranal, in male rats. *Phytomedicine*, 15(8), 491–495.
15. Kashani L, et al. (2013). Saffron for treatment of fluoxetine-induced sexual dysfunction in women: randomized double-blind placebo-controlled study. *Human Psychopharmacology*, 28(1), 54–60.

Age-Related Macular Degeneration (ARMD) & Safety

16. Falsini B, et al. (2010). Influence of saffron supplementation on retinal flicker sensitivity in early age-related macular degeneration. *Investigative Ophthalmology & Visual Science*, 51(12), 6118–6124.
17. Kianbakht S & Ghazavi A. (2011). Immunomodulatory effects of saffron: a randomized double-blind placebo-controlled clinical trial in healthy volunteers. *Phytotherapy Research*, 25(12), 1801–1805.
18. Marangoni D, et al. (2013). Functional effect of saffron supplementation and risk genotypes in early age-related macular degeneration: a preliminary report. *Journal of Translational Medicine*, 11, 228.
19. Moallem SA, et al. (2014). Evaluation of teratogenic effects of crocin and safranal, active ingredients of saffron, in mice. *Toxicology and Industrial Health*, 30(4), 332–340.
20. Piccardi M, et al. (2012). A longitudinal follow-up study of saffron supplementation in early age-related macular degeneration: sustained benefits to central retinal function. *Evidence-Based Complementary and Alternative Medicine*, 2012, Article ID 429124.